Effect of Ubiquinone on diabetes with coronary heart disease

Effect of Ubiquinone on inflammation and oxidative stress status among type 2 diabetes patients with coronary heart disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014111920007N1

Enrollment

Registered

2015-06-09

Start date

2015-05-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic ischaemic heart disease. Chronic ischaemic heart disease

Interventions

Intervention 1: Control group: Placebo, daily, 8 weeks orally. Intervention 2: Intervention group: ubiquinone tablet, 100 mg, daily, for 8 weeks orally.

Treatment - Drugs

Control group: Placebo, daily, 8 weeks orally

Intervention group: ubiquinone tablet, 100 mg, daily, for 8 weeks orally.

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Subjects with 45-75 years old? diagnosed with type 2 diabetes with coronary heart disease . Exclusion Criteria:Patients who do not want to corporate? Diabetic patients who have others complications associated with diabetes such as: kidney disease? neuropathy and retinopathy? Patients with hypo and/or hyperthyroidism are excluded from this study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Advanced gylcation end Products (AGEs). Timepoint: Before and after intervention. Method of measurement: flourimetery.;Protein carbonyl. Timepoint: before and after intervention. Method of measurement: spectrophotometer.;MDA. Timepoint: before and after of Intervention. Method of measurement: ELISA.;LP(a). Timepoint: before and after Intervention. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyyed Mehdi Mirhashemi

Kashan University of Medical Sciences

mirhashemism@gmail.com; mirhashemi@kaums.ac.ir+98 31 5554 1112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026